

Claims

1. An anti-Siglec-9 antibody molecule or an anti-Siglec-9 binding fragment
5 thereof comprising:
- (i) a heavy chain variable region (VH) comprising a heavy chain complementarity determining region 1 (VHCDR1) amino acid sequence of SEQ ID NO: 1, a heavy chain complementarity determining region 2 (VHCDR2) amino acid sequence of SEQ ID NO: 2, and a heavy chain complementarity determining region 3 (VHCDR3) amino acid sequence of SEQ ID NO: 3; and
10 a light chain variable region (VL) comprising a light chain complementarity determining region 1 (VLCDR1) amino acid sequence of SEQ ID NO: 4, a light chain complementarity determining region 2 (VLCDR2) amino acid sequence of SEQ ID NO: 5, and a light chain complementarity determining region 3 (VLCDR3) amino acid sequence of SEQ ID NO: 6;
- or
- (ii) a heavy chain variable region (VH) comprising a heavy chain complementarity determining region 1 (VHCDR1) amino acid sequence of SEQ ID NO: 1, a heavy chain complementarity determining region 2 (VHCDR2) amino acid sequence of SEQ ID NO: 45, and a heavy chain complementarity determining region 3 (VHCDR3) amino acid sequence of SEQ ID NO: 3; and
20 a light chain variable region (VL) comprising a light chain complementarity determining region 1 (VLCDR1) amino acid sequence of SEQ ID NO: 46, a light chain complementarity determining region 2 (VLCDR2) amino acid sequence of SEQ ID NO: 5, and a light chain complementarity determining region 3 (VLCDR3) amino acid sequence of SEQ ID NO: 6.
2. The antibody molecule or binding fragment thereof of claim 1, comprising:
- (i) a heavy chain variable region (VH) comprising the amino acid sequence of
30 SEQ ID NO: 7, or an amino acid sequence having at least about 85%, 90%, 95%, or 99% sequence identity to SEQ ID NO: 7; and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO: 8, or an amino acid sequence having at least about 85%, 90%, 95%, or 99% sequence identity to SEQ ID NO: 8;
- or
- (ii) a heavy chain variable region (VH) comprising the amino acid sequence of
SEQ ID NO: 47, or an amino acid sequence having at least about 85%, 90%, 95%, or 99% sequence identity to SEQ ID NO: 47; and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO: 48, or an amino acid
40 sequence having at least about 85%, 90%, 95%, or 99% sequence identity to SEQ ID NO: 48.

3. The antibody molecule or binding fragment thereof of claims 1 or 2, comprising:

(i) a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO: 7, and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO: 8;

or

(ii) a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO: 47, and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO: 48.

4. A pharmaceutical composition comprising the antibody molecule or binding fragment thereof of any one of claims 1-3 and a pharmaceutically acceptable carrier, excipient or stabilizer.

5. A nucleic acid encoding the antibody heavy chain variable region and light chain variable region of the antibody molecule or binding fragment thereof of any one of claims 1-3.

6. An expression vector comprising the nucleic acid of claim 5.

7. A host cell comprising the nucleic acid of claim 5 or the expression vector of claim 6.

8. A method of producing an antibody molecule, the method comprising culturing the host cell of claim 7 under conditions suitable for gene expression.